Doctor profile · Federal record
Dr. Rina Anvekar, M.D.
Dermatology Physician (CMS: Dermatology) · New York, NY
- NPI 1801141858
- Accepts Medicare
- 32 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
5 E 98Th St Fl 5, Department of Dermatology
New York, NY 100296501
(212) 241-9728
fax (212) 987-1197
Credentials & registration
- NPI registered
- July 2012 — 14 yrs on file
- Profile last updated
- January 5, 2021
- Year of graduation
- 1994 — 32 yrs since
- Specialty taxonomy
- 207N00000X — NUCC code
- State license (1)
- New York #283723
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1801141858. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
1,174
Distinct HCPCS
10
Medicare allowed
$95,376
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 279 | 54 | $8 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 246 | 167 | $99 | |
17000 |
Destruction of precancer skin growth, 1 growth | 119 | 89 | $61 | |
99203 |
New patient office or other outpatient visit, 30-44 minutes | 110 | 110 | $122 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 70 | 47 | $141 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 61 | 38 | $62 | |
11104 |
Punch biopsy, first skin growth | 60 | 56 | $141 | |
11102 |
Biopsy of related skin growth, first growth | 45 | 43 | $111 | |
17110 |
Destruction of skin growth, 1-14 growths | 43 | 25 | $128 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 33 | 33 | $183 |
In context: peer comparison
Among 139 peers in New York Dermatology Physician, average services per provider: 182. This provider delivers 6.5× the peer median.Open Payments
Industry payments received
All-time total
$3,353
Transactions
86
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Janssen Biotech, INC. | 8 | $2,204.56 | |
| Abbvie INC. | 14 | $195.87 | |
| Genzyme Corporation | 9 | $137.46 | |
| Ucb, INC. | 16 | $133.80 | |
| Leo Pharma INC. | 7 | $120.04 | |
| Galderma Laboratories, L.P. | 7 | $113.96 | |
| Sun Pharmaceutical Industries INC. | 5 | $89.29 | |
| Incyte Corporation | 5 | $81.76 | |
| Arcutis Biotherapeutics, INC. | 4 | $64.19 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | 3 | $47.02 | |
| Lilly USA, LLC | 2 | $34.00 | |
| Regeneron Healthcare Solutions, INC. | 2 | $31.91 | |
| Amgen INC. | 2 | $30.96 | |
| Helsinn Therapeutics (U.S.), INC. | 1 | $19.38 | |
| Mallinckrodt Hospital Products INC. | 1 | $16.61 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
340
Patients
226
Total drug cost
$19,484
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Clobetasol Propionate | Generic | 99 | 65 | $5,025 |
| Imiquimod | Generic | 54 | 36 | $2,882 |
| Ketoconazole | Generic | 49 | 30 | $957 |
| Triamcinolone Acetonide | Generic | 47 | 41 | $666 |
| Mupirocin | Generic | 34 | 29 | $351 |
| Tacrolimus | Generic | 25 | 13 | $3,240 |
| Fluorouracil | Generic | 16 | 12 | $1,240 |
| Pimecrolimus | Generic | 16 | 0 | $5,123 |
Frequently asked questions
What is Dr. Rina Anvekar's medical specialty?
Dr. Rina Anvekar practices Dermatology Physician in New York, NY.
Where does Dr. Rina Anvekar practice?
Dr. Rina Anvekar practices at 5 E 98Th St Fl 5, New York, NY 100296501. Office phone: 2122419728.
What is Dr. Rina Anvekar's NPI?
Dr. Rina Anvekar's National Provider Identifier (NPI) is 1801141858, issued by NPPES.
Does Dr. Rina Anvekar accept Medicare assignment?
Yes. Dr. Rina Anvekar accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Rina Anvekar commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213); Destruction of precancer skin growth, 1 growth (HCPCS 17000). Source: CMS Medicare Physician & Other Practitioners file.